T. Davis, C. Proby, J. A. Strong
Jul 1, 1989
Citations
0
Influential Citations
5
Citations
Quality indicators
Journal
Diabetic Medicine
Abstract
Enprostil, a dehydro‐prostaglandin E2 analogue, has been tested as treatment for peptic ulcer. Its effect on blood glucose and lipid metabolism in Type 2 diabetes was assessed in a randomized, double‐blind trial. Fifteen patients on sulphonylurea therapy received, in addition, enprostil 35 μg or placebo thrice daily for two weeks, with a 2‐week washout before crossover. Data from 12 patients were analysed. After a 530 Cal test breakfast at the end of active treatment, plasma glucose rose from a fasting concentration similar to that after the last placebo dose (10.5 ± 0.8 (± SE) and 10.6 ± 1.1 mmol l−1 respectively) to 1, 2 and 3 h concentrations which were 1.5 to 2.1 mmol l−1 lower than on placebo (2 h concentration 14.6 ± 0.9 vs 16.4 ± 1.3 mmol l−1, p < 0.05). Serum fructosamine concentrations at the end of active treatment and placebo were 3.66 ± 0.22 and 3.78 ± 0.24 respectively (p = 0.051). No changes in fasting or post‐prandial insulin concentrations were observed. After 2 weeks of enprostil, fasting serum triglyceride (1.76 ± 0.18 mmol l−1) and total cholesterol (6.27 ± 0.29 mmol l−1) concentrations were lower than after placebo (2.14 ± 0.25 and 7.35 ± 0.46 mmol l−1, p = 0.031 and p = 0.002, respectively), the latter effect being primarily due to reduced LDL‐cholesterol. More patients had gastrointestinal side‐effects on enprostil than placebo (p = 0.03), but symptoms were usually mild and transient, and caused only one patient to be withdrawn. If well‐tolerated, enprostil might prove a useful adjunct in the management of some patients with Type 2 diabetes.